Agilis Biotherapeutics Updates Progress of its CNS Gene Therapy for AADC Deficiency – Business Wire (press release)
|
Agilis Biotherapeutics Updates Progress of its CNS Gene Therapy for AADC Deficiency
Business Wire (press release) CAMBRIDGE, Mass.–(BUSINESS WIRE)–Agilis Biotherapeutics, Inc. (Agilis), a biotechnology company advancing innovative DNA therapeutics for rare genetic diseases that affect the central nervous system (CNS), announced today that following a recent … |
